Second published study to demonstrate the potential therapeutic utility and mechanism of action of KETABET (patented combination of ketamine and betaine) in models of depression Repeated use of KETABET exhibits potential protective and reversing effects on ketamine-elicited psychotomimetic behaviors and cognitive impairments Supports clinical initiatives as a potential next generation ketamine…

Source

Previous articleField Trip Announces Intention to Make Applications on Behalf of Patients to Health Canada’s Special Access Program (SAP) for Access to Psilocybin and MDMA-Assisted Therapies
Next articleFilament Health Announces Health Canada Approval for Phase II Trial Administering New Psilocybin Microdose Formulation